Hervé Hoppenot, Incyte CEO

In­cyte touts mid-stage da­ta for new JAK in­hibitor but stops short of se­lect­ing PhI­II dose

In­cyte is rolling out more mid-stage da­ta for its next-gen oral JAK in­hibitor, this time in an in­di­ca­tion where it’s re­cent­ly scored an ap­proval with an­oth­er drug.

Over the week­end at the 2023 Amer­i­can Acad­e­my of Der­ma­tol­ogy An­nu­al Meet­ing, the com­pa­ny spelled out re­sults from a Phase IIb tri­al of povorci­tinib among pa­tients with ex­ten­sive non­seg­men­tal vi­tili­go, a con­di­tion where peo­ple’s skin los­es col­or. In the study, the once-dai­ly pill helped more pa­tients than place­bo re­gain col­or on their skin, as mea­sured by a score of de­pig­men­ta­tion called T-VASI (to­tal Vi­tili­go Area Scor­ing In­dex).

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters